Santen Pharmaceutical (4536) Fundamentals 2026 — P/E 17.4x, Revenue Analysis | SniperIQ
Santen Pharmaceutical (4536) is a JP-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥639.2B, trading at ¥1987.00 on the JPX. This SniperIQ fundamentals page covers Santen Pharmaceutical's valuation (P/E 17.4x, P/B 2.2x), profitability (net margin 12.8%), revenue (¥291.6B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Santen Pharmaceutical's market cap?
Santen Pharmaceutical (4536) has a market capitalization of approximately ¥639.2B, trading at ¥1987.00 on the JPX. Market cap moves with the live share price.
What is Santen Pharmaceutical's P/E ratio?
Santen Pharmaceutical's trailing twelve-month P/E ratio is 17.4x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Santen Pharmaceutical?
Santen Pharmaceutical runs a net profit margin of 12.8%, a gross margin of 55.2%, and an operating margin of 15.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Santen Pharmaceutical generate?
Santen Pharmaceutical reported revenue of ¥291.6B for fiscal year 2026, with net income of ¥37.4B and earnings per share (EPS) of 114.04. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Santen Pharmaceutical pay a dividend?
Santen Pharmaceutical offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Santen Pharmaceutical financially healthy?
Santen Pharmaceutical carries a debt-to-equity ratio of 0.12x and a current ratio of 2.60x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Santen Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Santen Pharmaceutical (4536) the key facts are: market cap ¥639.2B, P/E 17.4x, revenue ¥291.6B, 52-week range 1458-2254. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Santen Pharmaceutical's full fundamentals live
Get Santen Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.